DFS - 85,0±6,8% (n=108; ev=6) STANDARD-RISK GROUP (SR) if available FC MRD < 0,1% or M1/ M2 marrow on day 15 HIGH-RISK GROUP (HR) IR and, if available.

Slides:

Advertisements

Similar presentations

Minimal Residual Disease in Hematologic Neoplasms Lloyd M. Stoolman, M.D. Professor of Pathology and Director, Clinical and Research Flow Cytometry Laboratories.

Advertisements

Acquired Aplastic Anaemia – Trends in treatment and Bone Marrow Transplantation Vikas Gupta, MD Blood and Marrow Transplant Program Princess Margaret Hospital.

Adult ALL – therapeutic strategies, including Burkitt

台北榮總血液腫瘤科楊元豪 / 高志平大夫. 2 Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative treatment in patients.

Treatment For Newly Diagnosed Myeloma

Quality Control in Immunophenotyping Dr. N. Varma Prof. & Head – Hematology Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh.

Childhood Leukaemia Aengus S. O’Marcaigh, M.D., F.R.C.P.I., F.A.A.P. Department of Paediatric Haematology &Oncology Our Lady’s Hospital for Sick Children.

Childhood Acute Lymphoblastic Leukemia Kelsey Shaffer CHTN Staff Meeting Presentation.

Activity Faculty Scott C. Howard, MD, MSc University of Tennessee College of Health Sciences Memphis, TN.

Acute lymphoblastic leukemia (ALL)

Classification of Microarray Data. Sample Preparation Hybridization Array design Probe design Question Experimental Design Buy Chip/Array Statistical.

Classification of Microarray Data. Sample Preparation Hybridization Array design Probe design Question Experimental Design Buy Chip/Array Statistical.

Kovacs G et al. Proc ASH 2014;Abstract 23.

Acute lymphoblastic leukemia (ALL)

Identification and Diagnosis of the Acute Leukemias

Chronic Lymphocytic Leukemia. Definition Clonal B cell malignancy. Progressive accumulation of long lived mature lymphocytes. Increase in anti-apoptotic.

Flow Cytometric Abnormalities in Myelodysplastic Syndrome Raida Oudat,MD Consultant Hematopathologist at Princess Iman Research and Laboratory Sciences.

Clinical Characteristics and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia With the t(4;ll) (q21;q23) By Ching-Hon Pui, Lawrence S. Frankel,

Conclusions We have developed a robust, quality controlled, sensitive method for MRD assessment in precursor B cell ALL which can be replicated in a multi.

The acute Leukemias are clonal hematopoietic malignant disease that arise from the malignant T r a n s f o r m a t i o n of an early Hematopoietic stem.

Pei Lin, MD Department of Hematopathology UT M.D. Anderson Cancer Center, Houston, TX Monitoring of Minimal Residual Disease Principles and Applications.

PCA, Clustering and Classification by Agnieszka S. Juncker Part of the slides is adapted from Chris Workman.

Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.

Chronic lymphocytic leukemia What is C.L.L. ? a chronic disease one particular type of lymphocyte (B-cells) accumulates. not rapidly growing and proliferating.

Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results.

Ibrutinib in Combination with Rituximab (iR) Is Well Tolerated and Induces a High Rate of Durable Remissions in Patients with High- Risk Chronic Lymphocytic.

New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.

Minimal Residual Disease(MRD) detections by Flow Cytometry in Acute Leukemia 혈액학파트 안 미 숙.

MRD testing: which platforms, which patients?

19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL

eCSI case 2 – November 2016 Jyotinder Nain Punia, MD

Monitoring of minimal residual disease in acute myeloid leukemia

Materials and methods:

IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.

Monitoring of minimal residual disease among multiple myeloma patients after autologous stem cell transplantation Fidan Akhundova, Larisa Mendeleeva, Irina.

Image 1 Detection of minimal residual disease (MRD) in consecutive bone marrow (BM) samples from a patient with relapse (A) and a patient still in remission.

Figure 2 Percentage of CD19+/CD34+ cells with decreased CD81 median fluorescence intensity (MFI;

Oil Red O positive vacuolated blasts in a case of CD45 negative, CD19 negative B- lymphoblastic leukemia Diana O. Treaba, MD, Allison Chen, Chad Ellermeier,

Early T-Cell Precursor ALL in 5 Year Old Female

بسم الله الرحمن الرحيم قَالُوا سُبْحَانَكَ لا عِلْمَ لَنَا إلاَّ مَا عَلَّمْتَنَا إنَّكَ أَنتَ العَلِيمُ الحَكِيمُ صدق الله العظيم ( البقرة 32 )

STUDY ON FEATURES OF CLINIC, BIOCLINIC AND DIAGNOSIS THE SUBTYPE OF ACUTE LEUKEMIA IN VIETTIEP FRIENDSHIP HOSPITAL, Dr: Pham Thi Loc Hematology.

Program Goals Case 1: Woman With MDS Risk: Cytogenetic Subgroups.

UNDERSTANDING RISK STRATIFICATION IN PAH:

How I treat hairy cell leukemia

Fenaux P et al. Lancet Oncol 2009;10(3):

Case:2 leukemia دينا نعمان جرادة جيهان ايمن مقاط.

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after.

دانشگاه شهیدرجایی تهران

PCA, Clustering and Classification by Agnieszka S. Juncker

FAB Classification of ALL

Diagnostic Hematology

تعهدات مشتری در کنوانسیون بیع بین المللی

A Effect of GO on survival stratified by CD33 expression on CD34+ blasts B Effect of GO dose on survival stratified by CD33 expression on CD34+ blasts.

What is the best frontline regimen for CLL patients

Example of algorithm for clinical assessment of patients at risk of non-alcoholic fatty liver disease Example of algorithm for clinical assessment.

New ELN Recommendations

Dendritic Cell Therapies for Hematologic Malignancies

The Role of Measurable Residual Disease in AML

Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.

Neoplastic disorder.

Feasibility of minimal residual disease studies by multiparametric flow cytometry for acute myeloid leukemia in a developing country by Lorena Lobo de.

Hematopoietic potential of HEP from patient-specific iPSC may be reduced. Hematopoietic potential of HEP from patient-specific iPSC may be reduced. (A)

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Minimal Residual Disease and Hematologic Malignancies

MRD Analysis in Chronic Lymphocytic Leukemia

Superior Survival of Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation Compared with Chemotherapy Alone Used as Post-Remission Therapy.

Kantarjian HM et al. Blood 2008;112:Abstract 635.

Presentation transcript:

DFS - 85,0±6,8% (n=108; ev=6)

STANDARD-RISK GROUP (SR) if available FC MRD < 0,1% or M1/ M2 marrow on day 15 HIGH-RISK GROUP (HR) IR and, if available FC MRD >10% or M3 marrow on day 15 SR if available FC MRD >10% INTERMEDIATE-RISK GROUP (IR) All patients who are not stratified to SR or HR are intermediate risk patients.

 Identify residual leukemia blasts in blood and bone marrow by microscopic analysis on 15 and 33 days.  Morphological assessment can be imprecise.  Measurement of MRD can be used to monitor treatment response much more precisely than morphological screening.

 Using 3-color flow cytometry on 15 day CD19 + CD ,6% NC CD19 + CD10 + CD ,6% NC CD19 + CD34 + 0,06% NC CD19 + CD34 + CD ,06% NC

 67 patients  64 patients with immunophenotype pre-pre B  2 patients with pro B immunophenotype  1 patient with pre B immunophenotype  Age group 6 months-16 years

CD19/CD10/CD34 CD19/CD10/CD45 or\and CD19/CD34/CD45 50 pt 1.Syto16/CD10/CD45/CD19 17pt 2. CD20/CD10/CD34/CD19 3 CD10/CD58/CD34/CD19

 31 patients  MRD < 0,1% – 19,4% ( 6 of 31)  MRD <0,1-10% – у 74 % (23 of 31)  MRD ≥10,0% – у 6,6% (2 of 31);

 30 patients  MRD <0,1-10% – у 86,6% (26 of 30)  MRD ≥10,0% – у13,4% (4 of 30) ;

 6 patients  MRD ≥10,0% - 100% (6 of 6)

Risk Group Morphological screening + MRD STANDARD-RISK GROUP (SR) 46,3% (31 )43.3% ( 29) INTERMEDIATE-RISK GROUP (IR) 44.8% (30)38.8%(26) HIGH-RISK GROUP (HR) 8.9% (6)17.9%(12)

 We can use MRD as independent prognostic factor in childhood  We can use MRD as tool for risk-group classification during front-line therapy  We can use MRD for adjust treatment intensity.

Thanks for you attention.